Understanding HPPD to Prioritize Harm Reduction of a Very Real Psychedelic Risk
“HPPD is precisely the kind of risk that could fall through the cracks,” says journalist Ed Prideaux, who suffers from the condition and advocates for more research.
Psychedelic Spotlight News
Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy
Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy
When it comes to treating mental health conditions with psychedelic therapy, one of the most promising compounds is DMT, the main ingredient in the brew ayahuasca. While DMT may have many potential advantages over other similar compounds such as psilocybin, for example, its short duration of effect, the hallucination can be very intense.
It is an open question whether the mental health benefits we see from psychedelic therapy are due to the experience one undergoes when having a hallucination, or whether it comes strictly from the drug’s effects on the brain. If it is the latter, then hypothetically speaking, we could create a version of DMT that does not cause a hallucination.
Enter Psilera Biosciences.
Psilera is a psychedelic medicines company working to create next-generation psychedelics for use in therapeutic settings. Specifically, they aim to create non-psychedelic versions of classical psychedelics such as psilocybin, LSD and DMT.
PSIL-002 is Psilera’s version of non-hallucinogenic DMT. They recently completed a pre-clinical trial in mice that showed that their version of DMT was safe and non-psychedelic. Now they have to show that their version of DMT can treat depression and addiction, starting with alcoholism.
If Psilera’s DMT can treat these mental health conditions equally as well as regular DMT, but without the intense hallucination, then PSIL-002 would probably be the better compound.
It is exciting to see Psilera’s scientists working on answering the following questions:
Can DMT treat depression?
Can psychedelics help with depression?
Can psychedelics help with Mental Health?
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Video editing: @themyaholy @Psy_holy
#DMT #DEPRESSION #PSYCHEDELICTHERAPY
Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect
Chief Medical Officer Guy Goodwin calls study “a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy.”
“Taking the leap” on Plant Medicines and Psilocybin with Formed NHL Enforcer Riley Cote
In today’s Psychedelic Spotlight episode, we see David Flores and…
Psychedelics and Women’s Health – What We DON’T Know
In today’s interview, we sit down with the CEO of…
Psychedelic Business Spotlight – December 10
This week in psychedelic business news: Wesana Health files a new patent, Silo Pharma is granted a patent, and 2 companies explore a merger.
Juan Pablo Cappello – “We’re NOT a Psychedelics Company, We’re a Mental Wellness Company” | Nue.Life
In today’s sneak peek we see Juan Pablo Capello, co-founder…
Non-Hallucinogenic DMT? Psilera Bioscience Reports Progress on ‘Well-Tolerated’ Derivative
Further in vivo studies with PSIL-002 will evaluate its antidepressant, anxiolytic, and anti-addictive properties, specifically targeting alcohol consumption.
You Can Make ‘Bad Trips’ Good with Storytelling, Psychedelics Study Shows
Evidence supports the idea that the possibly unpleasant nature of the psychedelic experience is an integral part of its therapeutic benefits.
Toronto Moves to Decriminalize Psychedelics
Proposed legislation decriminalizes personal possession and use of all illegal drugs in an effort to focus on health and social equity instead of criminalization.
End of content
End of content